Researchers developing a novel nasal spray presented their work at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego, Nov. 2-6.
Venkata Yellepeddi, Ph.D., along with his colleagues from Roseman University of Health Sciences, Henderson, Nevada, have developed a preservative-free device-driven prochlorperazine nasal spray.
“Prochloperazine is a dopamine receptor antagonist that is widely used as an anti-nausea medication. Comparative clinical studies have shown that prochloperazine provides better pain relief than other anti-migraine drugs such as sumatriptan, metoclopramide, and ketorolac,” said Yellepeddi. “Currently, there are no marketed nasal spray formulations of prochlorperazine available for the treatment of migraine. Prochlorperazine is only available in tablet form, which has delayed onset of action.”
Yellepeddi and his team believe that a nasal spray version of prochloperazine will not only be effective but fast acting as well. Because the spray does not contain preservatives such as benzalkonium chloride and potassium sorbate, it won’t have preservative-related side effects like nose irritation.
The next stage of the research is to test the safety and efficacy of the spray.